|
US5192537A
(en)
*
|
1984-03-30 |
1993-03-09 |
Cellcor Inc. |
Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
|
|
US5766920A
(en)
*
|
1982-08-11 |
1998-06-16 |
Cellcor, Inc. |
Ex vivo activation of immune cells
|
|
IL69686A
(en)
*
|
1983-09-11 |
1988-03-31 |
Yeda Res & Dev |
Compositions containing cell membrane proteins and process for their preparation
|
|
US4883662A
(en)
*
|
1984-04-10 |
1989-11-28 |
Clinical Biotechnologies, Inc. |
Method of increasing natural killer cell population of cancer patients
|
|
US5556620A
(en)
*
|
1985-02-05 |
1996-09-17 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor-1 to enhance wound healing
|
|
US5837229A
(en)
*
|
1985-02-05 |
1998-11-17 |
Chiron Corporation |
Uses of recombinant colony stimulating factor-1
|
|
US5308626A
(en)
*
|
1985-06-28 |
1994-05-03 |
Toni N. Mariani |
Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
|
|
US4902288A
(en)
*
|
1985-12-03 |
1990-02-20 |
Marylou Ingram |
Implantable immunotherapy system using stimulated cells
|
|
EP0302894B1
(de)
*
|
1986-04-28 |
1992-11-19 |
Endotronics Inc. |
Zuchtverfahren für leukocyten
|
|
US5002879A
(en)
*
|
1986-05-06 |
1991-03-26 |
Merrell Dow Pharmaceuticals |
Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
|
|
US4829002A
(en)
*
|
1986-05-12 |
1989-05-09 |
Baxter International Inc. |
System for metering nutrient media to cell culture containers and method
|
|
US4937194A
(en)
*
|
1986-05-12 |
1990-06-26 |
Baxter International Inc. |
Method for metering nutrient media to cell culture containers
|
|
US4971795A
(en)
*
|
1986-07-08 |
1990-11-20 |
Biomira, Inc. |
Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype
|
|
WO1988000970A2
(en)
*
|
1986-08-08 |
1988-02-11 |
Regents Of The University Of Minnesota |
Method of culturing leukocytes
|
|
ATE107861T1
(de)
*
|
1986-09-19 |
1994-07-15 |
Oncogen |
Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.
|
|
US4861589A
(en)
*
|
1987-03-23 |
1989-08-29 |
Trustees Of Boston University |
Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
|
|
US4808151A
(en)
*
|
1987-04-27 |
1989-02-28 |
E. I. Du Pont De Nemours And Company |
Simplified method for the preparation of human lymphokine activated killer cells
|
|
JPH02501534A
(ja)
*
|
1987-09-22 |
1990-05-31 |
バンデンバーク・アーサー・アレン |
細胞表面決定基の発現および機能を選択的に調節する方法およびこれによりつくられる新規な人間細胞の産生
|
|
US5041289A
(en)
*
|
1987-11-13 |
1991-08-20 |
Becton Dickinson And Company |
Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
|
|
AU2925789A
(en)
*
|
1987-12-17 |
1989-07-19 |
Browning's Clinical Pathology Services Limited |
Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
|
|
US5057423A
(en)
*
|
1987-12-18 |
1991-10-15 |
University Of Pittsburgh |
Method for the preparation of pure LAK-active lymphocytes
|
|
US5066489A
(en)
*
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
|
CA1329119C
(en)
*
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Cytotoxic therapy
|
|
US5120525A
(en)
*
|
1988-03-29 |
1992-06-09 |
Immunomedics, Inc. |
Radiolabeled antibody cytotoxic therapy of cancer
|
|
US20030232010A2
(en)
*
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
|
US5278143A
(en)
*
|
1988-04-25 |
1994-01-11 |
Trustees Of Boston University |
Prophylactic and therapeutic methods for treating interleukin-mediated edemas
|
|
FR2635527B1
(fr)
*
|
1988-07-28 |
1992-06-12 |
Roussel Uclaf |
Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
|
|
ATE147633T1
(de)
*
|
1988-10-27 |
1997-02-15 |
Univ Minnesota |
Immunhilfsmittel aus liposome enthaltend lymphokin il -2
|
|
GB8826298D0
(en)
*
|
1988-11-10 |
1988-12-14 |
Williams N S |
Production of lak cells compositions containing them & their use in cancer therapy
|
|
US6143508A
(en)
*
|
1989-06-29 |
2000-11-07 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Device and process for cell capture and recovery
|
|
CA1340565C
(en)
*
|
1989-06-29 |
1999-05-25 |
Thomas B. Okarma |
Device and process for cell capture and recovery
|
|
US5108760A
(en)
*
|
1989-07-21 |
1992-04-28 |
Terumo Corporation |
Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides
|
|
US5126132A
(en)
*
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
CA2066645A1
(en)
*
|
1989-09-14 |
1991-03-15 |
Richard A. Knazek |
Method for the production of in vitro expanded lymphoid cells for use in adoptive immunotherapy
|
|
JPH0728732B2
(ja)
*
|
1990-04-17 |
1995-04-05 |
日本石油株式会社 |
動物細胞増殖促進剤及び無血清培地
|
|
US5344755A
(en)
*
|
1990-04-21 |
1994-09-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for detecting immune system dysfunction in asymptomatic, HIV-scropositive individuals
|
|
US5766897A
(en)
*
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
|
US20030064480A1
(en)
*
|
1990-06-28 |
2003-04-03 |
Leander Lauffer |
Fusion proteins with immunoglobulin portions, the preparation and use thereof
|
|
US5229115A
(en)
*
|
1990-07-26 |
1993-07-20 |
Immunex Corporation |
Adoptive immunotherapy with interleukin-7
|
|
DK0567586T3
(da)
*
|
1991-01-16 |
1995-12-04 |
Schering Corp |
Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
|
US5843728A
(en)
*
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US5912170A
(en)
*
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
|
US5725855A
(en)
*
|
1991-04-05 |
1998-03-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
|
|
EP0578740A4
(en)
*
|
1991-04-05 |
1995-12-20 |
Univ Minnesota |
Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
|
|
US5199942A
(en)
*
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
IE922233A1
(en)
*
|
1991-07-10 |
1993-01-13 |
Augusto C Ochoa |
Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
|
|
WO1993003770A1
(en)
*
|
1991-08-23 |
1993-03-04 |
Board Of Regents Of The University Of Nebraska |
Method and compositions for cellular reprogramming
|
|
EP0624095B2
(de)
*
|
1991-12-31 |
2005-07-20 |
Zymogenetics, Inc. |
Verfahren und zusammensetzungen zur verminderung von blutverlust
|
|
US5296353A
(en)
*
|
1992-04-06 |
1994-03-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Evaluation and treatment of patients with progessive immunosuppression
|
|
US5556763A
(en)
*
|
1992-04-06 |
1996-09-17 |
United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Evaluation and treatment of patients with progressive immunosuppression
|
|
US5229109A
(en)
*
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
WO2003040165A2
(en)
|
2000-10-19 |
2003-05-15 |
Epimmune Inc. |
Hla class i and ii binding peptides and their uses
|
|
TW381026B
(en)
*
|
1993-01-13 |
2000-02-01 |
Schering Corp |
Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
|
|
US5670352A
(en)
*
|
1993-03-18 |
1997-09-23 |
Behringwerke Aktiengesellschaft |
Stable growth transformation of human T-lymphocytes by Herpesvirus saimiri (H. saimiri) subgroup C
|
|
EP0702563B1
(de)
*
|
1993-05-27 |
2003-08-06 |
EntreMed, Inc. |
Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
|
|
US5536642A
(en)
*
|
1993-09-09 |
1996-07-16 |
Barbera-Guillem; Emilio |
Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
|
|
US5750119A
(en)
*
|
1994-01-13 |
1998-05-12 |
Mount Sinai School Of Medicine Of The City University Of New York |
Immunotherapeutic stress protein-peptide complexes against cancer
|
|
US5997873A
(en)
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
|
US5961979A
(en)
*
|
1994-03-16 |
1999-10-05 |
Mount Sinai School Of Medicine Of The City University Of New York |
Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
|
|
IL112969A
(en)
*
|
1994-03-17 |
2001-05-20 |
Baxter Int |
Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
|
|
US5709995A
(en)
*
|
1994-03-17 |
1998-01-20 |
The Scripps Research Institute |
Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
|
|
EP0775197A1
(de)
*
|
1994-08-08 |
1997-05-28 |
Maxim Pharmaceuticals, Inc. |
Verstärkte aktivierung von natürlicher killerzellen durch verwendung von einem fängern oder hemmern des wasserstoffperoxids
|
|
US6045802A
(en)
*
|
1994-10-03 |
2000-04-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
|
|
ATE197765T1
(de)
|
1994-10-03 |
2000-12-15 |
Us Gov Health & Human Serv |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
|
US5935847A
(en)
*
|
1994-10-28 |
1999-08-10 |
Baxter International Inc. |
Multilayer gas-permeable container for the culture of adherent and non-adherent cells
|
|
US6297046B1
(en)
|
1994-10-28 |
2001-10-02 |
Baxter International Inc. |
Multilayer gas-permeable container for the culture of adherent and non-adherent cells
|
|
US7361332B2
(en)
|
1995-03-17 |
2008-04-22 |
The Regents Of The University Of California |
Treating tumors using implants comprising combinations of allogeneic cells
|
|
US6391404B1
(en)
|
1995-06-07 |
2002-05-21 |
Baxter International Inc. |
Coextruded multilayer film materials and containers made therefrom
|
|
US6024220A
(en)
*
|
1995-06-07 |
2000-02-15 |
Baxter International Inc. |
Encapsulated seam for multilayer materials
|
|
US20020182730A1
(en)
*
|
1995-07-26 |
2002-12-05 |
Micheal L. Gruenberg |
Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
|
|
US5627070A
(en)
*
|
1995-07-26 |
1997-05-06 |
Celltherapy, Inc. |
Cell growing device for in vitro cell population expansion
|
|
US5837251A
(en)
*
|
1995-09-13 |
1998-11-17 |
Fordham University |
Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
|
|
US5935576A
(en)
|
1995-09-13 |
1999-08-10 |
Fordham University |
Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
|
|
US5985270A
(en)
*
|
1995-09-13 |
1999-11-16 |
Fordham University |
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
|
|
US6805861B2
(en)
|
1996-01-17 |
2004-10-19 |
Imperial College Innovations Limited |
Immunotherapy using cytotoxic T lymphocytes (CTL)
|
|
AU737243B2
(en)
|
1996-07-03 |
2001-08-16 |
Merial, Inc. |
Recombinant canine adenovirus (CAV) containing exogenous DNA
|
|
US6130087A
(en)
*
|
1996-10-07 |
2000-10-10 |
Fordham University |
Methods for generating cytotoxic T cells in vitro
|
|
US5830464A
(en)
|
1997-02-07 |
1998-11-03 |
Fordham University |
Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
|
|
US6017540A
(en)
*
|
1997-02-07 |
2000-01-25 |
Fordham University |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
|
|
US5981472A
(en)
*
|
1997-02-21 |
1999-11-09 |
Dx/Ibr Corporation |
Methods for treating diseases
|
|
US6884414B1
(en)
*
|
1997-04-30 |
2005-04-26 |
Mount Sinai School Of Medicine Of New York University |
Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
|
|
US6872518B2
(en)
|
1997-09-22 |
2005-03-29 |
University Of Rochester |
Methods for selecting polynucleotides encoding T cell epitopes
|
|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
|
US5948646A
(en)
|
1997-12-11 |
1999-09-07 |
Fordham University |
Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
|
|
ES2355483T3
(es)
*
|
1998-02-20 |
2011-03-28 |
University Of Miami |
Complejo de proteina de choque térmico modificada-péptido antigénico.
|
|
DK1060247T3
(da)
|
1998-02-24 |
2009-01-26 |
Sisters Of Providence In Orego |
Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
|
|
US6790604B1
(en)
|
1998-05-12 |
2004-09-14 |
Stefan A. Cohen |
Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
|
|
ES2326146T3
(es)
|
1998-06-17 |
2009-10-01 |
Idm Pharma, Inc. |
Peptidos de union a hla y sus usos.
|
|
US6168785B1
(en)
*
|
1998-07-16 |
2001-01-02 |
Institut Pasteur |
Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
|
|
US6929791B2
(en)
|
1998-07-16 |
2005-08-16 |
Institut Pasteur |
Peptides of IL-2 and derivatives thereof
|
|
US20020092987A1
(en)
*
|
1998-09-05 |
2002-07-18 |
Taehee Cho |
Photo detect device using quantum dots and materialization method thereof
|
|
US6451316B1
(en)
|
1998-10-05 |
2002-09-17 |
University Of Conneticut Health Center |
Methods for generating antigen-reactive T cells in vitro
|
|
DE69942100D1
(de)
|
1998-10-20 |
2010-04-15 |
Androclus Technologies S R L I |
Künstliche antigen-spezifischen zellen und zugehörige verfahren
|
|
US6787154B2
(en)
*
|
1998-10-20 |
2004-09-07 |
Salvatore Albani |
Artificial antigen presenting cells
|
|
US7807377B2
(en)
|
1998-10-20 |
2010-10-05 |
Salvatore Albani |
Method of isolating antigen-specific T cells employing artificial antigen presenting cells
|
|
US6656471B1
(en)
|
1998-11-17 |
2003-12-02 |
Board Of Regents, The University Of Texas System |
HIV-specific T-cell induction
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
WO2001010912A1
(en)
|
1999-08-09 |
2001-02-15 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
US20040266834A1
(en)
*
|
1999-10-14 |
2004-12-30 |
Copland John A. |
Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
US20030194696A1
(en)
*
|
2000-03-28 |
2003-10-16 |
University Of Rochester |
Methods of producing a library and methods of selecting polynucleotides of interest
|
|
JP2003528605A
(ja)
*
|
2000-03-28 |
2003-09-30 |
ユニヴァーシティー オヴ ロチェスター |
ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
|
|
US7449557B2
(en)
|
2000-06-02 |
2008-11-11 |
University Of Connecticut Health Center |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
|
CZ2003214A3
(cs)
|
2000-06-29 |
2003-08-13 |
Merck Patent Gmbh |
Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
|
|
ES2282148T3
(es)
*
|
2000-11-30 |
2007-10-16 |
Imperial Innovations Limited |
Metodos y moleculas inmunoterapeuticos.
|
|
EP1356048A2
(de)
|
2000-12-04 |
2003-10-29 |
Argonex Pharmaceuticals |
Zytotoxisch t-lymphozyte induzierende immunogene zur krebsvorbeugung,behandlung, und diagnose
|
|
US7919467B2
(en)
*
|
2000-12-04 |
2011-04-05 |
Immunotope, Inc. |
Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
|
|
US6855925B2
(en)
*
|
2001-02-14 |
2005-02-15 |
Picoliter Inc. |
Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
|
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
|
FR2821947B1
(fr)
*
|
2001-03-12 |
2003-05-16 |
Canon Kk |
Procede et dispositif de validation de parametres definissant une image
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
|
HK1079705A1
(zh)
*
|
2001-08-20 |
2006-04-13 |
University Of Connecticut Health Center |
包含用於治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
|
|
US20030134415A1
(en)
*
|
2001-09-19 |
2003-07-17 |
Gruenberg Micheal L. |
Th1 cell adoptive immunotherapy
|
|
AU2002341717A1
(en)
*
|
2001-09-17 |
2003-04-01 |
Medcell Biologics, Llc. |
Cell therapy system
|
|
US20030134341A1
(en)
*
|
2001-09-19 |
2003-07-17 |
Medcell Biologics, Llc. |
Th1 cell adoptive immunotherapy
|
|
RU2201762C1
(ru)
*
|
2001-10-09 |
2003-04-10 |
Свадовский Александр Игоревич |
Способ лечения внутримозговой опухоли головного мозга
|
|
CN1628167A
(zh)
*
|
2001-11-22 |
2005-06-15 |
医学基因公司 |
白细胞介素-2基因转移的淋巴因子活化的杀伤细胞
|
|
EP1454138B1
(de)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokine mit modulierter selektivität
|
|
US20040236514A1
(en)
*
|
2001-12-13 |
2004-11-25 |
Lee Stephen C. |
Controlling distribution of epitopes in polypeptide sequences
|
|
US20030175272A1
(en)
*
|
2002-03-07 |
2003-09-18 |
Medcell Biologics, Inc. |
Re-activated T-cells for adoptive immunotherapy
|
|
AU2003274463B2
(en)
|
2002-06-10 |
2009-10-29 |
University Of Rochester |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
|
US8034334B2
(en)
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
US9809654B2
(en)
*
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
|
ATE471946T1
(de)
|
2002-12-17 |
2010-07-15 |
Merck Patent Gmbh |
Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
|
|
JP2006514088A
(ja)
*
|
2003-02-20 |
2006-04-27 |
ユニバーシティー オブ コネティカット ヘルス センター |
癌および感染症の治療における熱ショックタンパク質またはα−2−マクログロブリンを含む組成物の使用方法
|
|
US7638122B2
(en)
|
2003-03-07 |
2009-12-29 |
University Of South Florida |
Stat3 antagonists and their use as vaccines against cancer
|
|
US20040242676A1
(en)
*
|
2003-05-30 |
2004-12-02 |
Alessi Thomas R. |
Method of mitigating the adverse effects of IL-2
|
|
WO2005044982A2
(en)
|
2003-09-05 |
2005-05-19 |
Oregon Health & Science University |
Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
|
|
US8541002B2
(en)
*
|
2003-09-12 |
2013-09-24 |
Agenus Inc. |
Vaccine for treatment and prevention of herpes simplex virus infection
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
JP5060134B2
(ja)
|
2003-12-12 |
2012-10-31 |
ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
ヒト細胞傷害性Tリンパ球のエピトープ及びそのMUC−1の非VNTR(non−variablenumberoftandemrepeatsequence)由来のアゴニストエピトープ
|
|
US7838503B2
(en)
*
|
2005-06-15 |
2010-11-23 |
Children's Medical Center Corporation |
Methods for extending the replicative lifespan of cells
|
|
EP1937307A4
(de)
*
|
2005-09-14 |
2009-05-13 |
Hutchinson Fred Cancer Res |
Spezifische entfernung von aktivierten immunzellen
|
|
US20070248628A1
(en)
*
|
2005-12-06 |
2007-10-25 |
Keller Lorraine H |
Immunogens in cancer stem cells
|
|
AU2007281934B2
(en)
|
2006-01-18 |
2012-11-15 |
University Of Chicago |
Compositions and methods related to Staphylococcal bacterium proteins
|
|
CA2643337C
(en)
*
|
2006-03-01 |
2016-01-12 |
Janssen Pharmaceutica N.V. |
Cancer treatment combining lymphodepleting agent with ctls and cytokines
|
|
US20080107668A1
(en)
*
|
2006-08-30 |
2008-05-08 |
Immunotope, Inc. |
Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
|
|
CA2700573C
(en)
|
2006-09-26 |
2016-11-22 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
|
WO2008039969A2
(en)
|
2006-09-28 |
2008-04-03 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
|
CN101548008B
(zh)
|
2006-10-04 |
2013-04-17 |
詹森药业有限公司 |
失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
|
|
US20080131415A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
EP2112930B1
(de)
*
|
2007-02-21 |
2017-01-11 |
Vaccinex, Inc. |
Modulation der nkt-zellaktivität mit antigenbeladenen cdid-molekülen
|
|
EP2155241A4
(de)
*
|
2007-05-04 |
2010-06-02 |
Boris Skurkovich |
Verhinderung von krebs durch immunisierung
|
|
US9181329B2
(en)
|
2007-08-31 |
2015-11-10 |
The University Of Chicago |
Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
|
|
KR20100072228A
(ko)
|
2007-08-31 |
2010-06-30 |
유니버시티 오브 시카고 |
스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
|
|
US9090875B2
(en)
|
2008-01-29 |
2015-07-28 |
Fred Hutchinson Cancer Research Center |
Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity
|
|
WO2009114085A2
(en)
|
2008-03-03 |
2009-09-17 |
The University Of Miami |
Allogeneic cancer cell-based immunotherapy
|
|
AU2009226077B2
(en)
|
2008-03-20 |
2012-04-19 |
University Of Miami |
Heat shock protein gp96 vaccination and methods of using same
|
|
WO2009139921A2
(en)
*
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
US8758765B2
(en)
*
|
2008-07-29 |
2014-06-24 |
The University Of Chicago |
Compositions and methods related to Staphylococcal bacterium proteins
|
|
PL2328923T3
(pl)
|
2008-09-02 |
2016-06-30 |
Cedars Sinai Medical Center |
Epitopy CD133
|
|
US20110262477A1
(en)
|
2008-10-06 |
2011-10-27 |
University Of Chicago |
Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
|
|
EP2358383A4
(de)
*
|
2008-11-21 |
2011-11-23 |
Univ Miami |
Hiv/siv-impfstoffe zur herstellung von schleimhaut- und systemimmunität
|
|
KR101928684B1
(ko)
|
2009-01-08 |
2018-12-12 |
앨버트 아인슈타인 컬리지 오브 메디신, 인크. |
세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도
|
|
HRP20160274T1
(hr)
|
2009-04-03 |
2016-04-08 |
University Of Chicago |
Pripravci i metode vezane za varijante proteina a (spa)
|
|
PL2427485T3
(pl)
|
2009-05-07 |
2017-10-31 |
Immunocellular Therapeutics Ltd |
Epitopy CD133
|
|
WO2011025572A1
(en)
|
2009-08-26 |
2011-03-03 |
Immunotope, Inc. |
Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
|
|
US8075895B2
(en)
|
2009-09-22 |
2011-12-13 |
Janssen Pharmaceutica N.V. |
Identification of antigenic peptides from multiple myeloma cells
|
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
EP2555794A4
(de)
|
2010-04-05 |
2014-01-15 |
Univ Chicago |
Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
|
|
US9115402B2
(en)
|
2010-05-14 |
2015-08-25 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of identifying tumor specific neoantigens
|
|
AU2011274367B2
(en)
|
2010-07-02 |
2015-04-23 |
The University Of Chicago |
Compositions and methods related to protein A (SpA) variants
|
|
JP5793194B2
(ja)
|
2010-09-09 |
2015-10-14 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
感染防御ブドウ球菌抗原が関与する方法および組成物
|
|
CA2816379A1
(en)
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
|
WO2012129514A1
(en)
|
2011-03-23 |
2012-09-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
EP2505640A1
(de)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
|
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
|
BR112013032421A2
(pt)
|
2011-06-29 |
2017-01-17 |
Immunotope Inc |
método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue
|
|
US9624284B2
(en)
|
2011-09-13 |
2017-04-18 |
Immunotope, Inc. |
Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer
|
|
EP3692794A1
(de)
|
2011-09-16 |
2020-08-12 |
Baylor College of Medicine |
Gegen die tumormikroumgebung gerichtete manipulierte nkt-zellen
|
|
EP2760995B1
(de)
|
2011-09-30 |
2019-08-07 |
The University Of Miami |
Aus der niere isolierte nierenstammzellen
|
|
WO2013162746A1
(en)
|
2012-04-26 |
2013-10-31 |
University Of Chicago |
Staphylococcal coagulase antigens and methods of their use
|
|
EP2934532B1
(de)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
|
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
|
WO2014127296A1
(en)
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd |
Cancer vaccines and vaccination methods
|
|
AU2014251207B2
(en)
|
2013-04-07 |
2019-06-13 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for personalized neoplasia vaccines
|
|
EP2997134B1
(de)
|
2013-05-14 |
2020-06-24 |
Board of Regents, The University of Texas System |
Menschliche anwendung manipulierter chimärer antigen-rezeptor (car)-t-zellen
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
JP7060324B2
(ja)
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ネオ抗原ワクチンによる併用療法
|
|
WO2015130488A2
(en)
|
2014-02-28 |
2015-09-03 |
Immunotope, Inc. |
Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
|
|
IL292038B2
(en)
|
2014-04-23 |
2024-12-01 |
Juno Therapeutics Inc |
Methods for enriching or producing immune cell populations for adoptive therapy
|
|
US20170158749A1
(en)
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
KR20160145186A
(ko)
|
2014-04-24 |
2016-12-19 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
|
|
EP3805371A1
(de)
|
2014-05-15 |
2021-04-14 |
National University of Singapore |
Modifizierte natürliche killerzellen und verwendungen davon
|
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
BR112017008042A2
(pt)
|
2014-10-20 |
2017-12-26 |
Juno Therapeutics Inc |
métodos e composições para dosagem em terapia de célula adotiva
|
|
JP6740234B2
(ja)
|
2014-11-05 |
2020-08-12 |
ジュノー セラピューティクス インコーポレイテッド |
形質導入および細胞プロセシングのための方法
|
|
CA2964783C
(en)
|
2014-11-05 |
2024-01-23 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
CA2964785A1
(en)
|
2014-11-05 |
2016-05-12 |
Board Of Regents, The University Of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
|
EP3227323B1
(de)
|
2014-12-03 |
2020-08-05 |
Juno Therapeutics, Inc. |
Verfahren und zusammensetzungen zur adoptiven zelltherapie
|
|
EP3234130B1
(de)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Verfahren zum profiling vom t-zell-rezeptor-repertoire
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
|
US10046047B2
(en)
|
2015-02-06 |
2018-08-14 |
Heat Biologics, Inc. |
Vector co-expressing vaccine and costimulatory molecules
|
|
JP6775515B2
(ja)
|
2015-03-11 |
2020-10-28 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
トランスポザーゼポリペプチド及びその使用
|
|
WO2016154585A1
(en)
|
2015-03-26 |
2016-09-29 |
Charles Sentman |
Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
|
EP3294324A1
(de)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Impfstoffe zur behandlung und prävention von krebs
|
|
JP6913032B2
(ja)
|
2015-05-20 |
2021-08-04 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
共通ネオ抗原
|
|
MX2017015239A
(es)
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
|
TW202241500A
(zh)
|
2015-06-09 |
2022-11-01 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
KR20180043800A
(ko)
|
2015-09-09 |
2018-04-30 |
이뮨 디자인 코포레이션 |
Ny-eso-1 특이적 tcrs 및 그의 사용 방법
|
|
EP3350212A1
(de)
|
2015-09-18 |
2018-07-25 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
T-zell-rezeptoren (tcr) und verwendungen davon zur diagnose und behandlung von diabetes
|
|
ES2768957T3
(es)
|
2015-09-24 |
2020-06-24 |
Abvitro Llc |
Composiciones de anticuerpos contra el VIH y métodos de uso
|
|
AU2016326734B2
(en)
|
2015-09-25 |
2022-07-07 |
Abvitro Llc |
High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
|
|
US11365391B2
(en)
|
2015-09-28 |
2022-06-21 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
|
WO2017055273A1
(en)
|
2015-09-28 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Biofunctionalized nanoparticles and uses thereof in adoptive cell therapy
|
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
KR102908806B1
(ko)
|
2015-10-22 |
2026-01-07 |
주노 테라퓨틱스 게엠베하 |
세포의 배양 방법 및 이를 위한 키트와 장치
|
|
RU2761555C2
(ru)
|
2015-10-22 |
2021-12-09 |
Джуно Терапьютикс Гмбх |
Способы, наборы, средства и устройства для трансдукции
|
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
|
WO2017075147A1
(en)
|
2015-10-27 |
2017-05-04 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
MX2018006789A
(es)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Receptores quimericos modificados y composiciones y metodos relacionados.
|
|
US20200297760A1
(en)
|
2015-12-03 |
2020-09-24 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
|
WO2017096331A1
(en)
|
2015-12-04 |
2017-06-08 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
MA43759A
(fr)
|
2016-03-16 |
2018-11-28 |
Jason Connor |
Procédés de conception adaptative d'un régime de traitement et traitements associés
|
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
|
CN109476743A
(zh)
|
2016-03-22 |
2019-03-15 |
西雅图儿童医院(以西雅图儿童研究所名义营业) |
预防或缓解毒性的早期干预方法
|
|
CA3019835A1
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
|
EP3452499A2
(de)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Gentechnisch veränderte zellen und verfahren zur herstellung davon
|
|
WO2017210689A1
(en)
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
|
WO2017214207A2
(en)
|
2016-06-06 |
2017-12-14 |
Juno Therapeutics, Inc. |
Methods for the treatment of b cell malignancies using adoptive cell therapy
|
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
JP7054397B2
(ja)
|
2016-06-27 |
2022-04-13 |
ジュノー セラピューティクス インコーポレイテッド |
Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用
|
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
EP3269739A1
(de)
|
2016-07-15 |
2018-01-17 |
OGD2 Pharma |
Humanisierter antikörper gegen o-acetyliertes gd2-gangliosid (oacgd2)
|
|
EP3491022B1
(de)
|
2016-07-29 |
2025-09-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
|
|
JP7295795B2
(ja)
|
2016-07-29 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
免疫調節ポリペプチドならびに関連する組成物および方法
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
|
US11666649B2
(en)
|
2016-10-11 |
2023-06-06 |
University Of Miami |
Vectors and vaccine cells for immunity against Zika virus
|
|
EP3525803B1
(de)
|
2016-10-13 |
2022-12-07 |
Juno Therapeutics, Inc. |
Immuntherapieverfahren und zusammensetzungen mit tryptophan-stoffwechselweg-modulatoren
|
|
CA3042049A1
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
|
MA46716A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
|
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
|
US11590167B2
(en)
|
2016-12-03 |
2023-02-28 |
Juno Therapeutic, Inc. |
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
|
JP2019536460A
(ja)
|
2016-12-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Car−t細胞の調節方法
|
|
WO2018106732A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
|
WO2018132518A1
(en)
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
|
EP3571221A2
(de)
|
2017-01-20 |
2019-11-27 |
Juno Therapeutics GmbH |
Zelloberflächenkonjugate und verwandte zellzusammensetzungen und verfahren
|
|
EP3574116A1
(de)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
|
|
WO2018148180A2
(en)
|
2017-02-07 |
2018-08-16 |
Immune Design Corp. |
Materials and methods for identifying and treating cancer patients
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
MX2019010171A
(es)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
US11274160B2
(en)
|
2017-03-02 |
2022-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to Nectin-4 and uses thereof
|
|
AU2018227583B2
(en)
|
2017-03-03 |
2023-06-01 |
Obsidian Therapeutics, Inc. |
CD19 compositions and methods for immunotherapy
|
|
CN110913954A
(zh)
|
2017-03-03 |
2020-03-24 |
黑曜石疗法公司 |
免疫疗法的组合物和方法
|
|
EP3595705A1
(de)
|
2017-03-15 |
2020-01-22 |
Oxford BioMedica (UK) Limited |
Verfahren
|
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
|
WO2018187260A1
(en)
|
2017-04-04 |
2018-10-11 |
Heat Biologics, Inc. |
Intratumoral vaccination
|
|
EP3385373A1
(de)
|
2017-04-05 |
2018-10-10 |
Centro de Neurociências e Biologia Celular |
Zusammensetzungen zur umprogrammierung von zellen in dendritischen zellen oder antigen-präsentierende zellen, verfahren und verwendungen davon
|
|
US11345891B2
(en)
|
2017-04-05 |
2022-05-31 |
Asgard Therapeutics Ab |
Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
|
|
MX2019012017A
(es)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics Inc |
Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
|
|
AU2018260380B2
(en)
|
2017-04-27 |
2025-02-13 |
Juno Therapeutics Gmbh |
Oligomeric particle reagents and methods of use thereof
|
|
PL3618842T3
(pl)
|
2017-05-01 |
2024-02-19 |
Juno Therapeutics, Inc. |
Kombinacja terapii komórkowej i związku immunomodulującego
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
IL327498A
(en)
|
2017-06-02 |
2026-05-01 |
Juno Therapeutics Inc |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
EP3631468A1
(de)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Artikel zur herstellung und verfahren im zusammenhang mit der mit einer zelltherapie einherenden toxizität
|
|
CN110997902B
(zh)
|
2017-06-20 |
2021-11-30 |
居里研究所 |
Suv39h1缺陷的免疫细胞
|
|
IL299348B2
(en)
|
2017-06-28 |
2025-05-01 |
Regeneron Pharma |
Antigen-binding proteins against human papillomavirus and methods of using them
|
|
KR20200030593A
(ko)
|
2017-07-21 |
2020-03-20 |
버클리 라잇츠, 인크. |
항원 제시 합성 표면, 공유결합으로 관능화된 표면, 활성화된 t 세포, 및 이들의 용도
|
|
EP4516896A3
(de)
|
2017-08-09 |
2025-05-14 |
Juno Therapeutics, Inc. |
Verfahren und zusammensetzungen zur herstellung genetisch manipulierter zellen
|
|
KR102755437B1
(ko)
|
2017-08-09 |
2025-01-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
|
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
|
MA50079A
(fr)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics Inc |
Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
|
|
WO2019054865A1
(en)
|
2017-09-14 |
2019-03-21 |
ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) |
T-cell based immunotherapy
|
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
JP7357626B2
(ja)
|
2017-11-01 |
2023-10-06 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞の治療用組成物を生成するためのプロセス
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン,インコーポレイテッド |
免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素
|
|
AU2018359907A1
(en)
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
US11618884B2
(en)
|
2017-11-14 |
2023-04-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof
|
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
|
BR112020011223A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
marcadores fenotípicos para terapia celular e mé-todos relacionados
|
|
AU2018379091A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
EP3724225A1
(de)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5-bindende moleküle und verfahren zur verwendung davon
|
|
KR102327512B1
(ko)
|
2018-01-12 |
2021-11-17 |
주식회사 큐로셀 |
이원 shrna를 이용한 향상된 면역 세포 및 이를 포함하는 조성물
|
|
WO2019144095A1
(en)
|
2018-01-22 |
2019-07-25 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for car t cells
|
|
CN111971059A
(zh)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
使用过继细胞疗法和检查点抑制剂的组合疗法
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
DE102018108996B4
(de)
|
2018-02-09 |
2021-10-21 |
Immatics US, Inc. |
Verfahren zur Herstellung autologer T-Zellen
|
|
KR20200119840A
(ko)
|
2018-02-09 |
2020-10-20 |
이매틱스 유에스 인코포레이티드 |
T 세포의 제조 방법
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
SG11202008008UA
(en)
|
2018-02-21 |
2020-09-29 |
Univ Texas |
Universal antigen presenting cells and uses thereof
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Car t細胞療法のための配列決定法
|
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
EP3765053A2
(de)
|
2018-03-16 |
2021-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigene peptide aus urocortin 3 und verwendungen davon zur diagnose und behandlung von typ-1-diabetes
|
|
US20210023209A1
(en)
|
2018-03-16 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
WO2019175380A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
WO2019183500A1
(en)
|
2018-03-23 |
2019-09-26 |
Hung Chiung Yu |
Coccidioides antigens and methods of their use
|
|
US12441787B2
(en)
|
2018-04-02 |
2025-10-14 |
National University Of Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
CN112585277A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
表达重组受体的t细胞、相关多核苷酸和方法
|
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
EP3784688A2
(de)
|
2018-04-26 |
2021-03-03 |
Agenus Inc. |
Hitzeschockproteinbindende peptidzusammensetzungen und verfahren zu deren verwendung
|
|
BR112020022185A2
(pt)
|
2018-05-03 |
2021-02-02 |
Juno Therapeutics Inc |
terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
|
|
JP2021524233A
(ja)
|
2018-05-17 |
2021-09-13 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
薬物耐性免疫細胞及びその用途
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
LT4324851T
(lt)
|
2018-07-19 |
2025-10-10 |
|
Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
|
|
BR112021002390A2
(pt)
|
2018-08-09 |
2021-05-11 |
Juno Therapeutics Inc |
processos para gerar células modificadas e suas composições
|
|
CN112805378A
(zh)
|
2018-08-09 |
2021-05-14 |
朱诺治疗学股份有限公司 |
用于评估整合核酸的方法
|
|
CA3110089A1
(en)
|
2018-08-28 |
2020-03-05 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
|
|
WO2020044239A1
(en)
|
2018-08-29 |
2020-03-05 |
National University Of Singapore |
A method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
BR112021003757A2
(pt)
|
2018-08-31 |
2021-05-25 |
Invectys SA |
receptores de antígenos quiméricos contra múltiplas isoformas de hla-g
|
|
WO2020053122A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
|
US12239699B2
(en)
|
2018-09-11 |
2025-03-04 |
Shanghai Public Health Clinical Center |
Immunogen for broad-spectrum influenza vaccine and application thereof
|
|
KR20210063362A
(ko)
|
2018-09-21 |
2021-06-01 |
버클리 라잇츠, 인크. |
작용화된 웰 플레이트, 이의 제조 및 사용 방법
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020081875A1
(en)
|
2018-10-18 |
2020-04-23 |
Berkeley Lights, Inc. |
Proto-antigen-presenting synthetic surfaces, activated t cells, and uses thereof
|
|
CN113454110B
(zh)
|
2018-10-23 |
2024-07-02 |
里珍纳龙药品有限公司 |
Ny-eso-1 t细胞受体和其使用方法
|
|
WO2020089343A1
(en)
|
2018-10-31 |
2020-05-07 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
US12473345B2
(en)
|
2018-11-01 |
2025-11-18 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
CN119569895A
(zh)
|
2018-11-01 |
2025-03-07 |
朱诺治疗学股份有限公司 |
G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
|
|
US20210393691A1
(en)
|
2018-11-06 |
2021-12-23 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
|
CN113226340A
(zh)
|
2018-11-26 |
2021-08-06 |
恩卡尔塔公司 |
同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
|
|
EP4427810A3
(de)
|
2018-11-30 |
2024-12-04 |
Juno Therapeutics, Inc. |
Behandlungsverfahren mit adoptiver zelltherapie
|
|
KR20210110811A
(ko)
|
2018-11-30 |
2021-09-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법에서 b 세포 악성 종양의 투약 및 치료 방법
|
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
|
WO2020150832A1
(en)
|
2019-01-24 |
2020-07-30 |
Valorisation-Hsj, Limited Partnership |
Cell-specific transcriptional regulatory sequences and uses thereof
|
|
EA202192103A1
(ru)
|
2019-01-29 |
2021-12-15 |
Джуно Терапьютикс, Инк. |
Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
BR112021017744A2
(pt)
|
2019-03-08 |
2021-11-16 |
Obsidian Therapeutics Inc |
Composições e métodos de cd40l para regulação ajustável
|
|
US20200297768A1
(en)
|
2019-03-19 |
2020-09-24 |
Immatics US, Inc. |
Cd28 t cell cultures, compositions, and methods of using thereof
|
|
DE102019108125B4
(de)
|
2019-03-28 |
2022-02-03 |
Immatics US, Inc. |
Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
|
|
CN113811329B
(zh)
|
2019-04-19 |
2025-10-14 |
天科雅生物科技有限公司 |
抗pd-1抗体和其用途
|
|
SG11202111372VA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
CA3136737A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
JP2022533591A
(ja)
|
2019-05-14 |
2022-07-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
リンホトキシンアルファ遮断剤によりターゲットされた制御性t細胞及びその使用
|
|
CA3139981A1
(en)
|
2019-05-14 |
2020-11-19 |
The University Of Chicago |
Methods and compositions comprising staphylococcus protein a (spa) variants
|
|
CA3140668A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
SG11202113356XA
(en)
|
2019-06-12 |
2021-12-30 |
Juno Therapeutics Inc |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
|
WO2020252404A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
EP3994245A1
(de)
|
2019-07-05 |
2022-05-11 |
Case Western Reserve University |
Priming-medium und verfahren für stammzellenkultur und -therapie
|
|
WO2021009263A1
(en)
|
2019-07-16 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity for cd38 and uses thereof
|
|
EP4003407A1
(de)
|
2019-07-23 |
2022-06-01 |
Mnemo Therapeutics |
Suv39h1-deffiziente immunzellen
|
|
BR112022001194A2
(pt)
|
2019-07-24 |
2022-06-07 |
Regeneron Pharma |
Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
|
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
CN114651003A
(zh)
|
2019-09-10 |
2022-06-21 |
黑曜石疗法公司 |
用于可调调节的ca2-il15融合蛋白
|
|
US12528882B2
(en)
|
2019-09-13 |
2026-01-20 |
The University Of Chicago |
Methods and compositions for treating staphylococcal infections
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US20240083973A1
(en)
|
2019-10-09 |
2024-03-14 |
Ecole Normale Supérieure de Lyon |
T cells modified to express mutated cxcr4 or partially deleted and uses thereof
|
|
EP4045663A2
(de)
|
2019-10-16 |
2022-08-24 |
Umoja Biopharma, Inc. |
Retroviraler vektor zur universellen rezeptortherapie
|
|
MX2022005145A
(es)
|
2019-10-30 |
2022-06-29 |
Juno Therapeutics Gmbh |
Dispositivos de estimulación y/o selección celular y método de uso.
|
|
CN120605327A
(zh)
|
2019-11-06 |
2025-09-09 |
贝勒医学院 |
用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法
|
|
EP4054623A1
(de)
|
2019-11-07 |
2022-09-14 |
Juno Therapeutics, Inc. |
Kombination aus einer t-zelltherapie und (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidin-2,6-dion
|
|
WO2021105234A1
(en)
|
2019-11-25 |
2021-06-03 |
Asgard Therapeutics Ab |
Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof
|
|
EP4070097A1
(de)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Verfahren in zusammenhang mit toxizität und ansprechen bei einer zelltherapie zur behandlung von b-zell-malignitäten
|
|
EP4072682A1
(de)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper mit spezifität gegen her4 und verwendungen davon
|
|
AU2021205416B2
(en)
|
2020-01-08 |
2026-08-06 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
|
US20230071910A1
(en)
|
2020-01-24 |
2023-03-09 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
|
BR112022014461A2
(pt)
|
2020-01-24 |
2022-09-13 |
Regeneron Pharma |
Antígeno preferencialmente expresso em receptores de células t de melanoma (prame) e métodos de uso dos mesmos
|
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
JP2023519099A
(ja)
|
2020-02-12 |
2023-05-10 |
ジュノー セラピューティクス インコーポレイテッド |
Bcma指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用
|
|
EP4110823A1
(de)
|
2020-02-26 |
2023-01-04 |
A2 Biotherapeutics, Inc. |
Gegen mage-a3-peptid-mhc-komplexe gerichtete polypeptide und verfahren zu deren verwendung
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
CA3172447A1
(en)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
IL297147B1
(en)
|
2020-04-10 |
2026-05-01 |
Juno Therapeutics Inc |
Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
|
|
CA3181399A1
(en)
|
2020-04-28 |
2021-11-04 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
WO2021226063A1
(en)
|
2020-05-05 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Car comprising cd28 zeta and cd3 zeta
|
|
EP4149558A1
(de)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
KR20230024283A
(ko)
|
2020-05-13 |
2023-02-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
|
|
AU2021278356A1
(en)
|
2020-05-27 |
2022-11-03 |
Antion Biosciences Sa |
Adapter molecules to re-direct CAR T cells to an antigen of interest
|
|
WO2021257679A1
(en)
|
2020-06-17 |
2021-12-23 |
Janssen Biotech, Inc. |
Materials and methods for the manufacture of pluripotent stem cells
|
|
EP4171616A1
(de)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Manipulierte t-zellen zur bedingten expression eines rekombinanten rezeptors, zugehörige polynukleotide und verfahren
|
|
WO2022003568A1
(en)
|
2020-06-30 |
2022-01-06 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
CA3186065A1
(en)
|
2020-07-16 |
2022-01-20 |
Xiaohu FAN |
Cd19 binding molecules and uses thereof
|
|
US20230272039A1
(en)
|
2020-07-16 |
2023-08-31 |
Umoja Biopharma, Inc. |
Gated adapter targeting receptor
|
|
JP7846667B2
(ja)
|
2020-07-16 |
2026-04-15 |
レジェンド バイオテック アイルランド リミテッド |
Cd20結合分子及びその使用
|
|
CA3188656A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
JP7886313B2
(ja)
|
2020-07-30 |
2026-07-07 |
アンスティテュ・クリー |
Socs1に欠陥のある免疫細胞
|
|
EP4189071A1
(de)
|
2020-08-03 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Population von treg-zellen, die funktionell mit einer regulatorischen aktivität behaftet sind, und ihre verwendung zur adoptiven therapie
|
|
US11433100B2
(en)
|
2020-08-20 |
2022-09-06 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating ceacam positive cancers
|
|
EP4058474B1
(de)
|
2020-08-20 |
2024-05-08 |
A2 Biotherapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von egfr-positiven karzinomen
|
|
EP4097486A4
(de)
|
2020-08-20 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von ceacam-positivem krebs
|
|
WO2022040454A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
WO2022036458A1
(en)
|
2020-08-21 |
2022-02-24 |
12343096 Canada Inc. |
Modular assembly receptors and uses thereof
|
|
WO2022040631A1
(en)
|
2020-08-21 |
2022-02-24 |
Immatics US, Inc. |
Methods for isolating cd8+ selected t cells
|
|
EP4204546A1
(de)
|
2020-08-31 |
2023-07-05 |
City of Hope |
Neue zelllinien, verfahren zur herstellung natürlicher killerzellen und verwendungen davon
|
|
WO2022060904A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
WO2022074098A1
(en)
|
2020-10-08 |
2022-04-14 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Method for the identification of cancer neoantigens
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントcd3免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
US20220168407A1
(en)
|
2020-11-05 |
2022-06-02 |
Dcprime B.V. |
Use of tumor-independent antigens in immunotherapies
|
|
EP4251282A1
(de)
|
2020-11-27 |
2023-10-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur diagnose und überwachung von toxischer epidermaler nekrolyse
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
KR20230135075A
(ko)
|
2021-01-22 |
2023-09-22 |
멘두스 비.브이. |
종양 백신접종 방법
|
|
CA3207206A1
(en)
|
2021-02-01 |
2022-08-04 |
Lingfeng LIU |
Targeted protein degradation system and use thereof
|
|
IL304857A
(en)
|
2021-02-16 |
2023-10-01 |
A2 Biotherapeutics Inc |
Preparations and methods for treating HER2 POSITIVE cancer
|
|
JP2024507958A
(ja)
|
2021-02-26 |
2024-02-21 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
外因的に導入されたサイトカインを発現する操作された免疫エフェクター細胞
|
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
|
US20240168012A1
(en)
|
2021-03-22 |
2024-05-23 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
CN117858719A
(zh)
|
2021-03-29 |
2024-04-09 |
朱诺治疗学股份有限公司 |
使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
|
|
IL307257A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
|
|
JP2024512808A
(ja)
|
2021-04-05 |
2024-03-19 |
ヤンセン バイオテツク,インコーポレーテツド |
Calr及びjak2t細胞受容体
|
|
CN118201618A
(zh)
|
2021-04-16 |
2024-06-14 |
细胞基因公司 |
与bcma定向t细胞疗法的组合疗法
|
|
JP2024516308A
(ja)
|
2021-05-04 |
2024-04-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Mage-a4特異性を有するキメラ抗原受容体及びその使用
|
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
|
US20250304915A1
(en)
|
2021-05-25 |
2025-10-02 |
Institut Curie |
Myeloid Cells Overexpressing BCL2
|
|
JP2024528077A
(ja)
|
2021-07-30 |
2024-07-26 |
▲い▼尊生物医薬(浙江)有限公司 |
汎用型t細胞およびその応用
|
|
US20230089392A1
(en)
|
2021-09-20 |
2023-03-23 |
Immatics US, Inc. |
Monocyte depletion of t cells populations for t-cell therapy
|
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
EP4433512A4
(de)
|
2021-11-19 |
2025-12-31 |
Univ Pennsylvania |
Manipuliertes pan-leukozytenantigen cd45 zur erleichterung der car-t-zelltherapie
|
|
JP2025501272A
(ja)
|
2021-12-28 |
2025-01-17 |
ムネモ・セラピューティクス |
不活性化されたsuv39h1及び改変tcrを有する免疫細胞
|
|
AU2023209589A1
(en)
|
2022-01-21 |
2024-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Modulation of suv39h1 expression by rnas
|
|
AU2023217968A1
(en)
|
2022-02-09 |
2024-09-26 |
Janssen Biotech, Inc. |
Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
|
|
WO2023156587A1
(en)
|
2022-02-18 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
|
AU2023225954A1
(en)
|
2022-02-22 |
2024-09-05 |
Deka Biosciences, Inc. |
Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins
|
|
IL314801A
(en)
|
2022-02-22 |
2024-10-01 |
Juno Therapeutics Inc |
Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
|
|
CN119156403A
(zh)
|
2022-03-08 |
2024-12-17 |
阿伦蒂斯治疗股份公司 |
抗紧密连接蛋白-1抗体增加t细胞可用性的用途
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4279085A1
(de)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Zusammensetzungen und verfahren zum behandeln eines refraktären oder rezidivierenden krebses oder einer chronischen infektionskrankheit
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023237663A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
|
|
JP2025521543A
(ja)
|
2022-06-22 |
2025-07-10 |
ジュノー セラピューティクス インコーポレイテッド |
Cd19標的car t細胞のセカンドライン治療のための処置方法
|
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
WO2024019984A1
(en)
|
2022-07-18 |
2024-01-25 |
Cargo Therapeutics, Inc. |
Cytokine receptor switch polypeptides and uses thereof
|
|
CN119907674A
(zh)
|
2022-07-22 |
2025-04-29 |
詹森生物科技公司 |
遗传指令向效应免疫细胞的增强转移
|
|
EP4565262A2
(de)
|
2022-08-05 |
2025-06-11 |
Juno Therapeutics, Inc. |
Chimäre antigenrezeptoren spezifisch für gprc5d und bcma
|
|
US20260061051A1
(en)
|
2022-08-26 |
2026-03-05 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
|
WO2024052318A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
|
EP4584291A1
(de)
|
2022-09-08 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Antikörper mit spezifität gegen ltbp2 und verwendungen davon
|
|
KR20250061756A
(ko)
|
2022-09-08 |
2025-05-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
|
WO2024091944A1
(en)
|
2022-10-25 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Split receptor switch polypeptides and uses thereof
|
|
EP4608854A2
(de)
|
2022-10-27 |
2025-09-03 |
Cargo Therapeutics, Inc. |
Zusammensetzungen und verfahren für allogene immuntherapien
|
|
EP4608856A1
(de)
|
2022-10-27 |
2025-09-03 |
CARGO Therapeutics, Inc. |
Zusammensetzungen und verfahren für verbesserte immuntherapien
|
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
|
US20260166082A1
(en)
|
2022-11-02 |
2026-06-18 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
WO2024123760A1
(en)
|
2022-12-05 |
2024-06-13 |
Cargo Therapeutics, Inc. |
Multiplex cell selection compositions and uses thereof
|
|
US20260207667A1
(en)
|
2022-12-13 |
2026-07-23 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
WO2024168276A2
(en)
|
2023-02-09 |
2024-08-15 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|
|
CN120957741A
(zh)
|
2023-03-13 |
2025-11-14 |
宾夕法尼亚大学董事会 |
用于肿瘤治疗的car修饰剂的产生
|
|
WO2024206155A1
(en)
|
2023-03-24 |
2024-10-03 |
Cornell University |
Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
EP4702132A1
(de)
|
2023-04-26 |
2026-03-04 |
Institut National de la Santé et de la Recherche Médicale |
Verfahren zur modulation der differenzierung und funktionen menschlicher dendritischer zellen
|
|
EP4720109A1
(de)
|
2023-05-25 |
2026-04-08 |
Regeneron Pharmaceuticals, Inc. |
T-zell-rezeptoren, die präsentierte hpv16-, mart1-, cmv-, ebv- oder influenza-peptide binden
|
|
WO2025029930A1
(en)
|
2023-07-31 |
2025-02-06 |
Legend Biotech Ireland Limited |
Cells overexpressing cd31 and methods of use thereof
|
|
WO2025049972A1
(en)
|
2023-09-01 |
2025-03-06 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|
|
EP4777540A1
(de)
|
2023-09-13 |
2026-07-22 |
Juno Therapeutics, Inc. |
Kombinationstherapien mit einer zelltherapie mit expression eines gprc5d-targeting-car sowie zugehörige verfahren und verwendungen
|
|
KR20260088542A
(ko)
|
2023-10-06 |
2026-06-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Gprc5d-표적화 car을 발현하는 세포 요법을 사용한 조합 요법 및 관련 방법 및 용도
|
|
WO2025085680A1
(en)
|
2023-10-17 |
2025-04-24 |
Cargo Therapeutics, Inc. |
Methods for manufacturing car t cells
|
|
WO2025082603A1
(en)
|
2023-10-18 |
2025-04-24 |
Institut Curie |
Engineered immune cells overexpressing cd74 molecule
|
|
WO2025090978A1
(en)
|
2023-10-26 |
2025-05-01 |
Cargo Therapeutics, Inc. |
Modified immune effector cells
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
WO2025125363A1
(en)
|
2023-12-11 |
2025-06-19 |
Institut National de la Santé et de la Recherche Médicale |
Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions
|
|
IL328711A
(en)
|
2023-12-13 |
2026-07-01 |
Umoja Biopharma Inc |
Myeloid cells derived from engineered induced stem cells and methods for differentiating and using them
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025245381A1
(en)
|
2024-05-23 |
2025-11-27 |
The Trustrees Of Dartmouth College |
Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
|
|
WO2025255030A1
(en)
|
2024-06-03 |
2025-12-11 |
Cornell University |
Interferon gamma responsive chimeric t cell costimulatory receptor
|
|
WO2026002973A1
(en)
|
2024-06-25 |
2026-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Host immune cells engineered to overexpress a foxk1 polypeptide
|
|
WO2026035951A2
(en)
|
2024-08-07 |
2026-02-12 |
Legend Biotech Ireland Limited |
Cells overexpressing cd43 and methods of use thereof
|
|
WO2026055226A1
(en)
|
2024-09-03 |
2026-03-12 |
Legend Biotech Ireland Limited |
Cells overexpressing b3gnt2 and methods of use thereof
|
|
WO2026086785A1
(en)
|
2024-10-21 |
2026-04-30 |
Shenzhen Wondercel Biotechnology Limited |
Eukaryotic cells expressing exogenous inosine monophosphate dehydrogenase comprising chimeric antigen receptor binding to gucy2c
|
|
WO2026136848A2
(en)
|
2024-12-20 |
2026-06-25 |
Juno Therapeutics, Inc. |
Cd70-targeted cars and engineered cells comprising same and related methods
|
|
WO2026136970A1
(en)
|
2024-12-20 |
2026-06-25 |
Cargo Therapeutics, Inc. |
Methods for manufacturing car t cells
|